Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 33

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
 Moderate
    Severe
    
    34 (50.7%)
    22 (32.8%)
    3 (4.5%)
    
    73 (52.5%)
    56 (40.3%)
    2 (1.4%)
    
    107 (51.9%)
    78 (37.9%)
    5 (2.4%)
  
    Any Serious TEAE
    5 (7.5%)
    8 (5.8%)
    13 (6.3%)
  
    Any Treatment-Related Serious TEAE
    0
    2 (1.4%)
    2 (1.0%)
  
    Any TEAE Leading to Treatment Discontinuation
    2 (3.0%)
    12 (8.6%)
    14 (6.8%)
  
    Any TEAE Leading to Study Withdrawal
    2 (3.0%)
    12 (8.6%)
    14 (6.8%)
  
    Any TEAE with Fatal Outcome 
    0
    0
    0

23

The Company believes these
findings from the Phase 2 results indicate that XPro may offer benefits to a readily identified subgroup of Alzheimer’s patients
across all ages with biomarker-defined neuroinflammation, regardless of comorbidities or ApoE4 status and potentially lays the foundation
for advancing XPro as a promising treatment for AD. The Company is planning an end-of-phase 2 meeting with the FDA, which is expected
to occur towards the end of 2025 or early 2026, to determine next steps and expects to be eligible for one of the accelerated pathways.

24

CORDStrom,
developed by INmune Bio circa 2020, represents a breakthrough in mesenchymal stromal cell technology. The CORDStrom platform leverages,
among other things, proprietary screening, pooling and expansion techniques to create off-the-shelf, allogeneic, pooled human umbilical
cord -derived mesenchymal stromal cells (HucMSCs) as medicines to treat complex inflammatory diseases. CORDStrom products are designed
to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured, potent cellular medicines that can be
produced